Tania Rivera-Baltanas

Tania Rivera-Baltanas

Auto-generated profile, based on publicly available information

Tania Rivera-Baltanas

Translational Neuroscience Group-CIBERSAM, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, 36213 Vigo, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Schizophrenia Research
Verified
Journal Article
Closed access
Daniela Rodrigues-AmorimDaniela Rodrigues-Amorim
Daniela Rodrigues-Amorim
TRTania Rivera-Baltanás
Tania Rivera-Baltanás
Carlos SpuchCarlos Spuch
Carlos Spuch
HCHector J. Caruncho
Hector J. Caruncho
ÁGÁfrica González-Fernández
África González-Fernández
RARoberto Carlos Agís-Balboa
Roberto Carlos Agís-Balboa

20 September 2019 in Clinical Eeg and Neuroscience
Verified
Journal Article
Closed access
PDF file
PFPatricia Fernández-Palleiro
Patricia Fernández-Palleiro
TRTania Rivera-Baltanás
Tania Rivera-Baltanás
Daniela Rodrigues-AmorimDaniela Rodrigues-Amorim
Daniela Rodrigues-Amorim
SFSonia Fernández-Gil
Sonia Fernández-Gil
MVMaría del Carmen Vallejo-Curto
María del Carmen Vallejo-Curto
Carlos SpuchCarlos Spuch
Carlos Spuch
Major depressive disorder (MDD) is a multidimensional disorder that is characterized by the presence of alterations in mood, cognitive capacity, sensorimotor, and homeostatic functions. Given that about half of the patients diagnosed with MDD do not respond to the various current treatments, new techniques are being sought to predict not only the course of the disease but also the characteristics that differentiate responders from non-responders. Using the electroencephalogram, a noninvasive and inexpensive tool, most studies have proposed that patients with MDD have some lateralization in brain electrical activity, with alterations in alpha and theta rhythms being observed, which would be related to dysfunctions in emotional capacity such as the absence or presence of responses to the different existing treatments. These alterations help in the identification of subjects at high risk of suffering from depression, in the differentiation into responders and nonresponders to various therapies (pharmacological, electroconvulsive therapy, and so on), as well as to establish in which period of the disease the treatment will be more effective. Although the data are still inconclusive and more research is needed, these alpha and theta neurophysiological markers could support future clinical practice when it comes to establishing an early diagnosis and treating state disorders more successfully and accurately of mood disorders.

1 November 2018 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
Daniela Rodrigues-AmorimDaniela Rodrigues-Amorim
Daniela Rodrigues-Amorim
TRTania Rivera-Baltanás
Tania Rivera-Baltanás
JBJoão Bessa
João Bessa
NSNuno Sousa
Nuno Sousa
MVMaría de Carmen Vallejo-Curto
María de Carmen Vallejo-Curto
Carlos SpuchCarlos Spuch
Carlos Spuch

1 October 2017 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
Daniela Rodrigues-AmorimDaniela Rodrigues-Amorim
Daniela Rodrigues-Amorim
TRTania Rivera-Baltanás
Tania Rivera-Baltanás
MLMarta López
Marta López
Carlos SpuchCarlos Spuch
Carlos Spuch
JOJose M. Olivares
Jose M. Olivares
RARoberto Carlos Agís-Balboa
Roberto Carlos Agís-Balboa

21 February 2018 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
Daniela Rodrigues-AmorimDaniela Rodrigues-Amorim
Daniela Rodrigues-Amorim
TRTania Rivera-Baltanás
Tania Rivera-Baltanás
BRBenito Regueiro
Benito Regueiro
Carlos SpuchCarlos Spuch
Carlos Spuch
MHMaría Elena de Las Heras
María Elena de Las Heras
RARoberto Carlos Agís-Balboa
Roberto Carlos Agís-Balboa
Objectives: Schizophrenia is a poorly understood chronic disease. Its pathophysiology is complex, dynamic, and linked to epigenetic mechanisms and microbiota involvement. Nowadays, correlating schizophrenia with the environment makes sense owing to its multidimensional implications: temporal and spatial variability. Microbiota involvement and epigenetic mechanisms are factors that are currently being considered to better understand another dimension of schizophrenia. Methods: This review summarises and discusses currently available information, focussing on the microbiota, epigenetic mechanisms, technological approaches aimed at performing exhaustive analyses of the microbiota, and psychotherapies, to establish future perspectives. Results: The connection between the microbiota, epigenetic mechanisms and technological developments allows for formulating new approaches objectively oriented towards the development of alternative psychotherapies that may help treat schizophrenia. Conclusions: In this review, the gut microbiota and epigenetic mechanisms were considered as key regulators, revealing a potential new aetiology of schizophrenia. Likewise, continuous technological advances (e.g. culturomics), aimed at the microbiota-gut–brain axis generate new evidence on this concept.

25 February 2016 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
HCHector J. Caruncho
Hector J. Caruncho
KBKyle Brymer
Kyle Brymer
RRRaquel Romay-Tallón
Raquel Romay-Tallón
MMMilann A. Mitchell
Milann A. Mitchell
TRTania Rivera-Baltanás
Tania Rivera-Baltanás
LKLisa E. Kalynchuk
Lisa E. Kalynchuk
The finding that reelin expression is significantly decreased in mood and psychotic disorders, together with evidence that reelin can regulate key aspects of hippocampal plasticity in the adult brain, brought our research group and others to study the possible role of reelin in the pathogenesis of depression. This review describes recent progress on this topic using an animal model of depression that makes use of repeated corticosterone injections. This methodology produces depression-like symptoms in both rats and mice that are reversed by antidepressant treatment. We have reported that corticosterone causes a decrease in the number of reelin-immunopositive cells in the dentate gyrus subgranular zone, where adult hippocampal neurogenesis takes place; that down-regulation of the number of reelin-positive cells closely parallels the development of a depression-like phenotype during repeated corticosterone treatment; that reelin downregulation alters the co-expression of reelin with neuronal nitric oxide synthase; that deficits in reelin might also create imbalances in glutamatergic and GABAergic circuits within the hippocampus and other limbic structures; and that co-treatment with antidepressant drugs prevents both reelin deficits and the development of a depression-like phenotype. We also observed alterations in the pattern of membrane protein clustering in peripheral lymphocytes in animals with low levels of reelin. Importantly, we found parallel changes in membrane protein clustering in depression patients, which differentiated two subpopulations of naïve depression patients that showed a different therapeutic response to antidepressant treatment. Here we review these findings and develop the hypothesis that restoring reelin-related function could represent a novel approach for antidepressant therapies.